JP6647592B2 - ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用 - Google Patents

ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用 Download PDF

Info

Publication number
JP6647592B2
JP6647592B2 JP2016524330A JP2016524330A JP6647592B2 JP 6647592 B2 JP6647592 B2 JP 6647592B2 JP 2016524330 A JP2016524330 A JP 2016524330A JP 2016524330 A JP2016524330 A JP 2016524330A JP 6647592 B2 JP6647592 B2 JP 6647592B2
Authority
JP
Japan
Prior art keywords
pyrrole
carboxylate
methyl
hexafluoropropan
octahydropyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016524330A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525092A5 (enExample
JP2016525092A (ja
Inventor
ジョーンズ，トッド，ケイ．
シザー，ジャスティン，エス．
グライス，シェリル，エー．
ワン，ドン−フイ
ウェバー，オリビア，ディー．
Original Assignee
ルンドベック ラ ホーヤ リサーチ センター，インク．
ルンドベック ラ ホーヤ リサーチ センター，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルンドベック ラ ホーヤ リサーチ センター，インク．, ルンドベック ラ ホーヤ リサーチ センター，インク． filed Critical ルンドベック ラ ホーヤ リサーチ センター，インク．
Publication of JP2016525092A publication Critical patent/JP2016525092A/ja
Publication of JP2016525092A5 publication Critical patent/JP2016525092A5/ja
Application granted granted Critical
Publication of JP6647592B2 publication Critical patent/JP6647592B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Virology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2016524330A 2013-07-03 2014-07-01 ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用 Expired - Fee Related JP6647592B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361842543P 2013-07-03 2013-07-03
US61/842,543 2013-07-03
PCT/US2014/045145 WO2015003002A1 (en) 2013-07-03 2014-07-01 Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof

Publications (3)

Publication Number Publication Date
JP2016525092A JP2016525092A (ja) 2016-08-22
JP2016525092A5 JP2016525092A5 (enExample) 2017-08-10
JP6647592B2 true JP6647592B2 (ja) 2020-02-14

Family

ID=52144176

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524330A Expired - Fee Related JP6647592B2 (ja) 2013-07-03 2014-07-01 ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用

Country Status (7)

Country Link
US (1) US9828379B2 (enExample)
EP (1) EP3016653A4 (enExample)
JP (1) JP6647592B2 (enExample)
CN (1) CN105517547A (enExample)
CA (1) CA2917050A1 (enExample)
MX (1) MX2015017961A (enExample)
WO (1) WO2015003002A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101653473B1 (ko) 2012-01-06 2016-09-01 어바이드 테라퓨틱스, 인크. 카르바메이트 화합물 및 그의 제조 및 이용 방법
WO2015003002A1 (en) 2013-07-03 2015-01-08 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
CR20180047A (es) 2015-07-31 2018-03-07 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4-hidroxibutan-2-il carbamato como inhibidores de magl
WO2017143283A1 (en) 2016-02-19 2017-08-24 Abide Therapeutics, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
US10030020B2 (en) 2016-05-12 2018-07-24 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
CN109996790B (zh) * 2016-09-19 2023-05-16 H.隆德贝克有限公司 哌嗪氨基甲酸酯及其制备和使用方法
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
KR102508739B1 (ko) 2016-11-16 2023-03-09 하. 룬드벡 아크티에셀스카브 Magl 억제제의 결정형
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
MX393241B (es) * 2016-11-16 2025-03-24 H Lundbeck As Formulaciones farmaceuticas.
MX2019008626A (es) * 2017-01-20 2019-09-19 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl).
CA3056076A1 (en) * 2017-03-13 2018-09-20 Abide Therapeutics, Inc. A substituted-heterocyclic-c(o)o-(substituted pyridin-3-yl)compound and its use as a dual magl and faah inhibitor
AU2018326497A1 (en) * 2017-08-29 2020-02-20 H. Lundbeck A/S. Spirocycle compounds and methods of making and using same
AU2018323459A1 (en) 2017-08-29 2020-02-20 H. Lundbeck A/S. Spirocycle compounds and methods of making and using same
US11274101B2 (en) 2017-09-29 2022-03-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
US11332453B2 (en) 2018-05-15 2022-05-17 H. Lundbeck A/S MAGL inhibitors
BR112021000109A2 (pt) * 2018-07-19 2021-03-30 Pfizer Inc. Compostos espiro heterocíclicos como inibidores de magl
WO2021062232A1 (en) * 2019-09-26 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for reducing rewarding effects of morphine without affecting its analgesic effects
CA3175210A1 (en) 2020-04-21 2021-10-28 Cheryl A. Grice Synthesis of a monoacylglycerol lipase inhibitor
US11434222B2 (en) 2020-11-13 2022-09-06 H. Lundbeck A/S MAGL inhibitors
KR20230166084A (ko) * 2021-04-01 2023-12-06 오노 야꾸힝 고교 가부시키가이샤 Abhd6 안타고니스트
KR20240128870A (ko) 2021-12-29 2024-08-27 싸이 테라퓨틱스, 인크. 모노아실글리세롤 리파아제(magl) 억제
IL316302A (en) 2022-05-04 2024-12-01 H Lundbeck As Crystalline form of 111333-hexafluoropro s-1-pyridazin-3-ylca azaspiro2.5octane-6- as a monoacylglycerol lipase inhibitor
WO2024168426A1 (en) * 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100326D0 (sv) * 2001-02-02 2001-02-02 Astrazeneca Ab New compounds
BR0207952A (pt) * 2001-03-07 2004-07-27 Pfizer Prod Inc Moduladores da atividade de receptores de quimiocina
RU2010140613A (ru) * 2008-03-05 2012-04-10 Таргасепт, Инк. (Us) Амиды диазабициклоалканов, селективные в отношении подтипа никотиновых ацетилхолиновых рецепторов
US8653263B2 (en) * 2009-10-23 2014-02-18 Janssen Pharmaceutica Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
JP2013521290A (ja) * 2010-03-04 2013-06-10 メルク・シャープ・エンド・ドーム・コーポレイション Ｍｇｌｕｒ２の正のアロステリックモジュレータ
EP2444084A1 (en) * 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
PT2900669T (pt) * 2012-09-25 2019-10-29 Hoffmann La Roche Derivados de hexahidropirrolo[3,4−c]pirrol e compostos relacionados enquanto inibidores da autotaxina (atx) e enquanto inibidores da produção de ácido lisofosfatídico (lpa) para o tratamento de, por exemplo, doenças renais
WO2015003002A1 (en) 2013-07-03 2015-01-08 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof

Also Published As

Publication number Publication date
EP3016653A4 (en) 2017-02-22
US9828379B2 (en) 2017-11-28
EP3016653A1 (en) 2016-05-11
MX2015017961A (es) 2016-10-14
JP2016525092A (ja) 2016-08-22
US20160137649A1 (en) 2016-05-19
WO2015003002A1 (en) 2015-01-08
CA2917050A1 (en) 2015-01-08
CN105517547A (zh) 2016-04-20

Similar Documents

Publication Publication Date Title
JP6647592B2 (ja) ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
CN107660199B (zh) 哌嗪氨基甲酸酯及其制备和使用方法
US10954236B2 (en) Tyrosine amide derivatives as Rho-Kinase inhibitors
JP7162622B2 (ja) ピラゾールｍａｇｌ阻害剤
TWI699364B (zh) ５-氯-２-二氟甲氧基苯基吡唑并嘧啶化合物、組合物及其使用方法
AU2011305568B2 (en) Imidazotriazinone compounds
EP3377060B1 (en) Pyrazole derivatives, processes for their preparation and uses thereof
ES2952332T3 (es) Compuestos espirocíclicos y sus métodos de preparación y uso
AU2018271876B2 (en) Pyrazole MAGL inhibitors
ES2861648T3 (es) Compuestos de espirociclo y procedimientos de fabricación y uso de los mismos
KR20100098714A (ko) 단백질 키나아제 저해물질로서의 벤조푸로피리미디논
AU2018236161B9 (en) Dual MAGL and FAAH inhibitors
CN116635028A (zh) c-MYC mRNA翻译调节剂及其在治疗癌症中的用途
JP7611900B2 (ja) 縮合複素環化合物
EP4393919A1 (en) Lsd1 modulators
JP2025526462A (ja) ハンチントン病を治療するための化合物
CN119233976A (zh) c-MYC mRNA翻译调节剂和其在癌症治疗中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170622

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180725

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190702

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191011

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191225

R150 Certificate of patent or registration of utility model

Ref document number: 6647592

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees